323
Participants
Start Date
February 14, 2018
Primary Completion Date
December 12, 2018
Study Completion Date
July 16, 2019
MT-6548
Oral tablet
Darbepoetin alfa
Intravenous administration
MT-6548-matching placebo
Oral tablet
Darbepoetin alfa-matching placebo
Intravenous administration
Research site, Aichi
Research site, Chiba
Research site, Fukui
Research site, Fukuoka
Research site, Fukushima
Research site, Gunma
Research site, Hiroshima
Research site, Hokkaido
Research site, Hyōgo
Research site, Ibaraki
Research site, Kagawa
Research site, Kagoshima
Research site, Kanagawa
Research site, Kumamoto
Research site, Kyoto
Research site, Miyagi
Research site, Nagano
Research site, Nagasaki
Research site, Okayama
Research site, Okinawa
Research site, Osaka
Research site, Ōita
Research site, Saitama
Research site, Shiga
Research site, Shizuoka
Research site, Tokushma
Research site, Tokyo
Research site, Yamagata
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
INDUSTRY